<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48840">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02470403</url>
  </required_header>
  <id_info>
    <org_study_id>CLIK066X2201</org_study_id>
    <nct_id>NCT02470403</nct_id>
  </id_info>
  <brief_title>Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel Group, 2-part Study Investigating the Effect of LIK066 on Body Weight in Dysglycemic (Prediabetes or Type 2 Diabetes) and Normoglycemic Patients With Elevated Body Mass Index</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 12-week study to assess LIK066 effect on body weight in diabetics, prediabetics and
      normoglycemic patients with elevated body mass index (BMI)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Percent change in body weight from baseline</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>To assess the effect of a 12-week treatment with LIK066 on body weight in dysglycemic and normoglycemic patients with elevated BMI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of patients with any adverse events, serious adverse events and death</measure>
    <time_frame>12 weeks</time_frame>
    <description>To assess the safety and tolerability of a 12-week treatment with LIK066 in dysglycemic and normoglycemic patients with elevated BMI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Percent change in body weight from baseline</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>To assess the effect of a 2-week treatment with LIK066 on body weight in dysglycemic and normoglycemic patients with elevated BMI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of patients with any adverse events, serious adverse events and death</measure>
    <time_frame>2 weeks</time_frame>
    <description>To assess the safety and tolerability of a 2-week treatment with LIK066 in dysglycemic and normoglycemic patients with elevated BMI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in body weight in dysglycemic patients and normoglycemic patients with elevated BMI</measure>
    <time_frame>Baseline, Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration of LIK066 at steady state (Cmax ss) in Part 1 of the study</measure>
    <time_frame>Day 14, Day 56 and Day 70 Predose. Day 84: predose, 0.5, 1, 1.5, 2, 3, 4, 6 and 24 h postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration of LIK066 at steady state (Tmax, ss) in Part 1 of the study</measure>
    <time_frame>Day 14, Day 56 and Day 70 Predose. Day 84: predose, 0.5, 1, 1.5, 2, 3, 4, 6 and 24 h postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time profile to the time of the last quantifiable concentration at steady state (AUClast, ss) of LIK066 in Part 1 of the study</measure>
    <time_frame>Day 14, Day 56 and Day 70 Predose. Day 84: predose, 0.5, 1, 1.5, 2, 3, 4, 6 and 24 h postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time profile to the time of next dosing at steady state (AUCtau, ss) of LIK066 in Part 1 of the study</measure>
    <time_frame>Day 14, Day 56 and Day 70 Predose. Day 84: predose, 0.5, 1, 1.5, 2, 3, 4, 6 and 24 h postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The apparent systemic clearance at steady state (CLss/F) of LIK066 following extra vascular administration in Part 1 of the study</measure>
    <time_frame>Day 14, Day 56 and Day 70 Predose. Day 84: predose, 0.5, 1, 1.5, 2, 3, 4, 6 and 24 h postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The apparent volume of distribution of LIK066 during the terminal elimination phase following extra vascular administration (Vz/F) in Part 1 of the study</measure>
    <time_frame>Day 14, Day 56 and Day 70 Predose. Day 84: predose, 0.5, 1, 1.5, 2, 3, 4, 6 and 24 h postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration of LIK066 (Cmax) in Part 2 of the study</measure>
    <time_frame>Day 1: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose. Day 7 Predose. Day 14: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration of LIK066 at steady state (Cmax ss) in Part 2 of the study</measure>
    <time_frame>Day 1: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose. Day 7 Predose. Day 14: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration of LIK066 (Tmax) in Part 2 of the study</measure>
    <time_frame>Day 1: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose. Day 7 Predose. Day 14: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration of LIK066 at steady state (Tmax, ss) in Part 2 of the study</measure>
    <time_frame>Day 1: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose. Day 7 Predose. Day 14: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time profile to the time of the last quantifiable concentration (AUClast) of LIK066 in Part 2 of the study</measure>
    <time_frame>Day 1: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose. Day 7 Predose. Day 14: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time profile to the time of the last quantifiable concentration at steady state (AUClast, ss) of LIK066 in Part 2 of the study</measure>
    <time_frame>Day 1: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose. Day 7 Predose. Day 14: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time profile to the time of next dosing (AUCtau) of LIK066 in Part 2 of the study</measure>
    <time_frame>Day 1: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose. Day 7 Predose. Day 14: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time profile to the time of next dosing at steady state (AUCtau, ss) of LIK066 in Part 2 of the study</measure>
    <time_frame>Day 1: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose. Day 7 Predose. Day 14: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The apparent systemic clearance at steady state (CLss/F) of LIK066 following extra vascular administration in Part 2 of the study</measure>
    <time_frame>Day 1: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose. Day 7 Predose. Day 14: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The apparent volume of distribution of LIK066 during the terminal elimination phase following extra vascular administration (Vz/F) in Part 2 of the study</measure>
    <time_frame>Day 1: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose. Day 7 Predose. Day 14: predose, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 9 h postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Elevated Body Mass Index</condition>
  <arm_group>
    <arm_group_label>LIK066 once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LIK066 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 three times daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LIK066 three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo once daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo three times daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 two times daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LIK066 two times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo two times daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo two times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LIK066</intervention_name>
    <description>LIK066 25 mg tablets</description>
    <arm_group_label>LIK066 once daily</arm_group_label>
    <arm_group_label>LIK066 three times daily</arm_group_label>
    <arm_group_label>LIK066 two times daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets</description>
    <arm_group_label>Placebo once daily</arm_group_label>
    <arm_group_label>Placebo three times daily</arm_group_label>
    <arm_group_label>Placebo two times daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with stable health condition as determined by past medical history, physical
             examination, electrocardiogram, and laboratory tests at screening.

          -  Patients with dysglycemia are patients with: Fasting plasma glucose &gt;100mg/dL (5.6
             mmol/L), or HbA1c &gt; 5.7% and &lt; 10% at screening.

          -  Fasting plasma glucose ≤250mg/dL (13.9 mmol/L) at screening.

          -  If treated with antidiabetic medications (other than prohibited medications),
             patients must be on a stable dose for 12 weeks prior to randomization and maintain
             the dose until the end of the study.

          -  Subjects must have a body mass index (BMI) within the range of 35 - 50 kg/m2 at
             screening, with stable body weight (± 5 kg) within 3 months prior to screening

        Exclusion Criteria:

          -  Pre-existing, clinically significant gastrointestinal, liver, cardiovascular, renal
             or other chronic medical condition which is considered serious or unstable, other
             than stable cardiovascular disease, treated hypertension, dyslipidemia or other
             stable chronic disorders

          -  Clinically significant GI disorder related to malabsorption or that may affect drug
             or glucose absorption or history of significant gastrointestinal surgery that could
             affect intestinal glucose absorption

          -  Enrollment in a diet, weight loss or exercise programs with the specific intent of
             losing weight, within 3 months prior to randomization, or clinical diagnosis of any
             eating disorder

          -  Pregnant or nursing (lactating) women, and women of child-bearing potential

        Other inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 25, 2016</lastchanged_date>
  <firstreceived_date>June 10, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dysglycemic, normoglycemic, prediabetes, type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
